Core Viewpoint - The company, Guangzhou Kingmed Diagnostics Group Co., Ltd., anticipates a net loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -130 million to -190 million yuan, which represents a reduction in losses compared to the previous year [2][3]. Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. - The expected net profit attributable to shareholders is projected to be between -130 million to -190 million yuan, with a year-on-year reduction in losses of 191.24 million to 251.24 million yuan [3]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -120 million to -180 million yuan [3]. Previous Year Performance - In the previous year, the total profit was -438.65 million yuan, with a net profit attributable to shareholders of -381.24 million yuan, and a net profit excluding non-recurring gains and losses of -237.98 million yuan [5]. - The basic earnings per share were -0.82 yuan [6]. Reasons for Performance Decline - Significant impairment provisions are expected due to prolonged aging of accounts receivable, with an estimated credit impairment loss of approximately 350 million to 390 million yuan for 2025 [7]. - The operating environment has been challenging due to economic cycles and macro policies, leading to lower-than-expected business revenue as the company optimizes its customer structure [7]. - Short-term adjustment costs have increased due to management efficiency improvements and internal resource integration, impacting current operating performance [7]. - Increased investment in digital transformation is expected to raise operational costs in the short term but aims to enhance future growth potential [8].
广州金域医学检验集团股份有限公司 2025年年度业绩预亏公告